ライフサイエンスコーパス: corticosteroid therapy

1 erapy (topical, regionally injected, or oral corticosteroid therapy).

2 all patients, and none responded to topical corticosteroid therapy.

3 % in ED visits, and 46% in the need for oral corticosteroid therapy.

4 asthma in spite of high-dose inhaled or oral corticosteroid therapy.

5 epartment (ED) visits, and the need for oral corticosteroid therapy.

6 less responsive to the beneficial effects of corticosteroid therapy.

7 mately 20% of icteric AIH presentations fail corticosteroid therapy.

8 lowing intravenous gamma globulin (IVIG) and corticosteroid therapy.

9 Both subtypes respond to corticosteroid therapy.

10 nize estrogen-promoted events in response to corticosteroid therapy.

11 osis of asthma, identifying those in need of corticosteroid therapy.

12 engraftment period and favorable response to corticosteroid therapy.

13 the diagnosis, especially before initiating corticosteroid therapy.

14 but aggressive disease that responds well to corticosteroid therapy.

15 ocular hypertensive response with the use of corticosteroid therapy.

16 patients do not respond well to conventional corticosteroid therapy.

17 solved disease and was unrelated to systemic corticosteroid therapy.

18 pients remain without the need for long-term corticosteroid therapy.

19 resses in only a minority of patients during corticosteroid therapy.

20 kin of the abdominal wall that resolved with corticosteroid therapy.

21 roids, and 20 (56%) were able to discontinue corticosteroid therapy.

22 ascular protective effect of acute high-dose corticosteroid therapy.

23 was reversed with the prompt institution of corticosteroid therapy.

24 grade I and IIA and were fully reversed with corticosteroid therapy.

25 nce oral corticosteroid use while on inhaled corticosteroid therapy.

26 ients (38%) developed diabetes during pulsed corticosteroid therapy.

27 month and 2 gm thereafter; and conventional corticosteroid therapy.

28 tient was successfully treated using topical corticosteroid therapy.

29 tructive pulmonary disease (COPD) respond to corticosteroid therapy.

30 0.20, n = 19, p < 0.001) and normalizes with corticosteroid therapy.

31 s documented in patients receiving long-term corticosteroid therapy.

32 veitis, which are often managed with chronic corticosteroid therapy.

33 nd one of complications related to long-term corticosteroid therapy.

34 ion of the effusion after the institution of corticosteroid therapy.

35 rease risk for this blinding complication of corticosteroid therapy.

36 evere pain, and a rapid response to systemic corticosteroid therapy.

37 loped clinical skin GVHD, which responded to corticosteroid therapy.

38 ation at 90 and 180 days after initiation of corticosteroid therapy.

39 commonly in patients who deteriorated during corticosteroid therapy.

40 It appears unresponsive to corticosteroid therapy.

41 ation of cyclophosphamide and institution of corticosteroid therapy.

42 pneumonitis is reversible and may respond to corticosteroid therapy.

43 of a 58-year-old patient undergoing empiric corticosteroid therapy.

44 t, or by differences in the use of antenatal corticosteroid therapy.

45 iving patients required maintenance low-dose corticosteroid therapy.

46 erlying chronic inflammatory disease or from corticosteroid therapy.

47 Nine patients received corticosteroid therapy.

48 sis, especially when treated with adjunctive corticosteroid therapy.

49 ion are important potential complications of corticosteroid therapy.

50 due to DRESS is poor and was not improved by corticosteroid therapy.

51 Six patients improved with corticosteroid therapy.

52 c and visual recovery was attained following corticosteroid therapy.

53 within 24 h of initiating high-dose systemic corticosteroid therapy.

54 dermatitis that was unresponsive to topical corticosteroid therapy.

55 COVID-19 patients, following tocilizumab and corticosteroid therapy.

56 1%) patients also having concurrent systemic corticosteroid therapy.

57 sed neutrophils and often poorly responds to corticosteroid therapy.

58 OR, 2.12; 95% CI, 1.36-3.29) associated with corticosteroid therapy.

59 symptomatic and endoscopic remission without corticosteroid therapy.

60 overlap syndrome might benefit from inhaled corticosteroid therapy.

61 to inhaled beta-agonist, antimuscarinic, and corticosteroid therapy.

62 on (n = 1), which resolved following topical corticosteroid therapy.

63 erage 5.5 months following the initiation of corticosteroid therapy.

64 oimmune-like hepatitis that is responsive to corticosteroid therapy.

65 subfield volume in humans receiving chronic corticosteroid therapy.

66 arter of patients with SAH do not respond to corticosteroid therapy.

67 Single and multiple courses of antenatal corticosteroid therapy.

68 linical examination as well as with systemic corticosteroid therapy.

69 or had contraindications to bevacizumab and corticosteroid therapies.

70 In respect to systemic corticosteroid therapy, 10 patients (18 of 51 eyes) were

71 1 of 27, 40.7%), dialysis (22 of 27, 81.5%), corticosteroid therapy (12 of 27, 44.4%), intensive care

72 layed resistance to combined vinblastine and corticosteroid therapy (21.9% v 3.3%; P = .001), showed

73 7 (3.2%) continued to receive long-term oral corticosteroid therapy, 5 (2.3%) received biologic thera

74 Antenatal corticosteroid therapy (ACT) is used clinically to prepa

75 Most studies have reported that corticosteroid therapy adversely influences influenza-re

76 a safe and effective alternative to topical corticosteroid therapy after cataract surgery.

77 rgeted trough levels of 5 to 7 ng/ml) and no corticosteroid therapy after the first week.

78 ral nutrition therapy is more effective than corticosteroid therapy alone in patients with severe AH.

79 compare the efficacy and safety of systemic corticosteroid therapy alone versus corticosteroid plus

80 d airway function when compared with inhaled corticosteroid therapy alone.

81 that cyclophosphamide therapy is superior to corticosteroid therapy alone.

82 All patients responded well to systemic corticosteroid therapy, although some had a relapse upon

83 All patients had failed high dose corticosteroid therapy and 144 (85%) of the 169 patients

84 erage 4.2 months following the initiation of corticosteroid therapy and 8% (9/105) were intolerant to

85 p avoid unnecessary morbidity from high-dose corticosteroid therapy and allow the most appropriate an

86 The role of systemic corticosteroid therapy and aspirin in NA-AION and of thr

87 be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify patients as

88 patitis of undetermined cause can respond to corticosteroid therapy and represent autoantibody-negati

89 ts with severe asthma are less responsive to corticosteroid therapy and show increased airway remodel

90 TAO treatment approaches, including systemic corticosteroid therapy and surgical decompression.

91 ray of effector T cells that persist despite corticosteroid therapy and sustain chronic, smoldering v

92 ant association between antecedent high-dose corticosteroid therapy and the development of SRC.

93 As adjunctive corticosteroid therapy and vitamin D have immunomodulato

94 in both blood and lung tissue in relation to corticosteroid therapy and vitamin D levels, especially

95 However, the efficacy of corticosteroid therapy and whether the therapy should be

96 myopathy who had not responded adequately to corticosteroid therapy and whose clinical course was fur

97 udesonide (Nefecon) or reduced-dose systemic corticosteroid therapy and, in Chinese patients, mycophe

98 90% (881) of the patients used inhaled corticosteroid therapy, and all patients continued to us

99 ntaneously--only to relapse after receipt of corticosteroid therapy, and clear again, 8.5 years later

100 ICI therapy cessation, prompt initiation of corticosteroid therapy, and escalation of therapy are al

101 but aggressive disease that responds well to corticosteroid therapy, and human leukocyte antigen DR4

102 Autoimmune hepatitis commonly relapses after corticosteroid therapy, and long-term management strateg

103 ed trends in the use of ventilatory support, corticosteroid therapy, antibiotic therapy, and patient

104 Early corticosteroid therapy appears to be critical for revers

105 ity evidence that periocular and intraocular corticosteroid therapies are effective and safe for the

106 ith severe asthma who require long-term oral corticosteroid therapy are at risk of unwanted effects.

107 infusion (IVIG), with or without additional corticosteroid therapy, are common options, but optimal

108 y high-volume saline irrigation with topical corticosteroid therapy as a first-line therapy for chron

109 The second case outlines the use of topical corticosteroid therapy as an adjunct to non-surgical per

110 y biliary cirrhosis entered remission during corticosteroid therapy as commonly as individuals with d

111 portion of patients who discontinued inhaled corticosteroid therapy as part of a phased-reduction pro

112 logical cirrhosis at presentation respond to corticosteroid therapy as well as patients without cirrh

113 whether benefit exists to combination NSAID/corticosteroid therapy, as well as whether NSAIDS can re

114 sits, and 44% reduction in the need for oral corticosteroid therapy at 48 months, the model simulated

115 High-dose corticosteroid therapy at diagnosis of mold infection wa

116 e patients had received a course of systemic corticosteroid therapy at the time of MB.

117 is not needed, but using concomitant pulsed corticosteroid therapy beyond 3 to 5 days requires an in

118 toms and infiltrates regressed after topical corticosteroid therapy, but recurred after each adalimum

119 disease persisted for nearly a month despite corticosteroid therapy, but resolved.

120 Autoimmune hepatitis may fail to respond to corticosteroid therapy, but the frequency and bases for

121 articularly following exposure cessation and corticosteroid therapy, but the time course to improveme

122 ho had persistent asthma and were prescribed corticosteroid therapy by the physician were also signif

123 conclusion, patients who respond to initial corticosteroid therapy can achieve a sustained remission

124 Corticosteroid therapy can be effective in patients with

125 Although corticosteroid therapy can increase survival in HIV-nega

126 utcomes in subjects randomized to continuous corticosteroid therapy (CCS) or early corticosteroid wit

127 ompare patterns of weight gain under chronic corticosteroid therapy (CCST) with that observed under e

128 Corticosteroid therapy consisted of either methylprednis

129 An overreliance on corticosteroid therapy contributes to much of the long-t

130 Efficacy of systemic corticosteroid therapy (CS) for long-term kidney surviva

131 AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associated risks

132 t high risk for asthma, two years of inhaled-corticosteroid therapy did not change the development of

133 compared with a single course, of antenatal corticosteroid therapy did not increase or decrease the

134 hil count is a promising biomarker to direct corticosteroid therapy during COPD exacerbations, but la

135 he usefulness of blood eosinophils to direct corticosteroid therapy during exacerbations.

136 , and systemic corticosteroid ( sCS systemic corticosteroid ) therapy effects were assessed in compar

137 adequately controlled asthma despite inhaled corticosteroid therapy, especially in periostin-high pat

138 systemic side effects compared with regional corticosteroid therapy, except for greater antibiotic us

139 s 50 years or older (or 40 years or older on corticosteroid therapy) expected to require NSAIDs for 1

140 ion, defined as inactive uveitis and no oral corticosteroid therapy for 2 consecutive study visits >=

141 Primary end point was the rate of CR without corticosteroid therapy for 2 months at month 12.

142 gh in patients without and with sCS systemic corticosteroid therapy for 5 days or fewer (area under t

143 decreased in patients receiving sCS systemic corticosteroid therapy for 6-14 days.

144 At month 12, the rate of CR without corticosteroid therapy for a minimum of 2 months was 72

145 that children who receive long-term inhaled corticosteroid therapy for asthma have height deficits 1

146 y of colchicine as an alternative to inhaled corticosteroid therapy for asthma is unknown.

147 Siplizumab administered with corticosteroid therapy for grade II or higher acute GVHD

148 regional corticosteroid injections and oral corticosteroid therapy for induction of remission.

149 s, with important limitations, suggests that corticosteroid therapy for presumed influenza-associated

150 observational studies investigating systemic corticosteroid therapy for presumed influenza-associated

151 spine occurred in association with long-term corticosteroid therapy for systemic lupus erythematosus.

152 es and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury.

153 t-line therapy for mild to moderate UC, with corticosteroid therapy for those who fail to achieve rem

154 was identified in 7 articles on intravitreal corticosteroid therapy for treatment of DME: triamcinolo

155 rance that the potential benefits of topical corticosteroid therapy, for treating pain and discomfort

156 Inhaled corticosteroid therapy has proven efficacy for asthmatic

157 ly completed randomized, controlled studies, corticosteroid therapy has proven to be efficacious in t

158 Corticosteroid therapy has shown some benefit in severe

159 suppressive measures, particularly high-dose corticosteroid therapy, has been reported variably, but

160 Despite continuing corticosteroid therapy, he died 21 days after admission

161 sts considering a 6-month course of systemic corticosteroid therapy; however, the efficacy of systemi

162 Nonadherence to inhaled corticosteroid therapy (ICS) is a major contributor to p

163 all investigated periocular and intraocular corticosteroid therapies improved VA, macular structure,

164 Topical corticosteroid therapy improved overall symptom scores (

165 Corticosteroid therapy improves survival in select patie

166 , and intracranial pressure decreased during corticosteroid therapy in all three.

167 tion to the variation in response to inhaled corticosteroid therapy in asthma.

168 a useful alternative to the over-reliance on corticosteroid therapy in atopic disease.

169 spitalizations, ED visits, and need for oral corticosteroid therapy in childhood asthma for planning

170 The effect of corticosteroid therapy in critically ill patients with l

171 Adjunctive systemic corticosteroid therapy in patients hospitalized with CAP

172 earch of trials that evaluated the effect of corticosteroid therapy in patients hospitalized with CAP

173 No consensus exists for adjusting inhaled corticosteroid therapy in patients with asthma.

174 placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbations of

175 nse prompted us to examine the role of early corticosteroid therapy in patients with moderate to seve

176 ovides similar survival benefits compared to corticosteroid therapy in severe AH.

177 f pIPA requires Aspergillus culture or prior corticosteroid therapy in this cohort of critically ill

178 The group suggested corticosteroid therapies (including budesonide for mild

179 ed the risk of UGIB; concomitant nsNSAID and corticosteroid therapies increased the IRR to the greate

180 Although he was treated with pulse corticosteroid therapy, interstitial pneumonia and media

181 Corticosteroid therapy is associated with improved 1-mon

182 Corticosteroid therapy is frequently used in septic pati

183 Corticosteroid therapy is independently associated with

184 Loss of this circadian rhythm during corticosteroid therapy is often associated with memory i

185 A single course of antenatal corticosteroid therapy is recommended for pregnant women

186 Empiric doxycycline and systemic corticosteroid therapy is recommended.

187 intervention; long-term therapy with inhaled corticosteroid therapy is safer than frequent bursts of

188 disease progression can be avoided if timely corticosteroid therapy is started.

189 Although corticosteroid therapy is the primary treatment for thes

190 Corticosteroid therapy is typically administered when a

191 le airway obstruction, withdrawal of inhaled corticosteroid therapy leads to a deterioration in venti

192 Eventually corticosteroid therapy led to complete and long lasting

193 Repeated lumbar punctures and corticosteroid therapy led to improvement in symptoms in

194 wing the institution of cyclophosphamide and corticosteroid therapy, longer-term management issues ca

195 evated C3a and anti-dsDNA levels, short-term corticosteroid therapy may avert a severe flare.

196 in animals and children have suggested that corticosteroid therapy may be a useful adjunct to conven

197 Adjunctive topical corticosteroid therapy may be associated with improved l

198 Corticosteroid therapy may be beneficial in those with i

199 Early institution of corticosteroid therapy may help in resolution of the inf

200 ds on cytokine synthesis in T cells, chronic corticosteroid therapy may indirectly exacerbate the lon

201 Use of prehospital systemic corticosteroid therapy may prevent the development of ac

202 Early corticosteroid therapy may prevent the development of su

203 For hospitalized adults with CAP, systemic corticosteroid therapy may reduce mortality by approxima

204 Although cycloplegic and corticosteroid therapy may resolve some entities, pars p

205 hCRF, as an alternative to corticosteroid therapy, may provide substantial benefits

206 ting that retinal vasculitis unresponsive to corticosteroid therapy maybe a poor prognostic sign.

207 Studies have suggested that primary corticosteroid therapy might be beneficial and that adve

208 ed assay, those seropositive by ELISA failed corticosteroid therapy more commonly (24% vs. 3%, P = .0

209 After intensified local corticosteroid therapy, most patients show stable visual

210 derate asthma controlled by low-dose inhaled corticosteroid therapy (n = 114 assigned to physician as

211 ALF, aspiration is more likely if there's no corticosteroid therapy, negative Aspergillus culture, an

212 tional symptoms, prompt response to systemic corticosteroid therapy, neutrophilia, and abrupt onset o

213 which suggested an adverse association with corticosteroid therapy (odds ratio, 3.90; 95% CI, 2.31-6

214 ients and assess the effect of ribavirin and corticosteroid therapy on the case-fatality rate, strati

215 During the initial period of high dose corticosteroid therapy, opening pressures on lumbar punc

216 Patients may be managed with corticosteroid therapy or the anti-CD20 monoclonal antib

217 aze scores of 0 or 0.5+ in both eyes without corticosteroid therapy or uveitis worsening.

218 ated with bolus impaction: swallowed topical corticosteroid therapy (OR 0.411, 95%-CI 0.203-0.835, P

219 istic regression modeling: swallowed topical corticosteroid therapy (OR 0.503, 95%-CI 0.255-0.993, P

220 itial pneumonia generally responds poorly to corticosteroid therapy, other forms of interstitial pneu

221 cacy of tamoxifen in humans as an adjunct to corticosteroid therapy over a period of 48 weeks.

222 han those without to have received intensive corticosteroid therapy (P<0.007), had virus isolated fro

223 Despite the efficacy of corticosteroid therapy, patients hospitalized for asthma

224 Cases refractory to corticosteroid therapy pose a clinical challenge(1,5) an

225 restimated in children who are responsive to corticosteroid therapy prescribed for a suspicion of min

226 an antilymphocyte preparation plus high dose corticosteroid therapy prior to conversion.

227 Corticosteroid therapy provides immediate benefit and ma

228 Compared with placebo, corticosteroid therapy reduced the risk of persistent or

229 Corticosteroid therapy reduces or prevents hepatic fibro

230 Corticosteroid therapy reduces the duration and severity

231 years, systemic adverse effects from inhaled corticosteroid therapy remains a complicated and controv

232 Postoperative corticosteroid therapy remains an area of debate without

233 Low-dose corticosteroid therapy reversed shock and showed nonsign

234 echanistic basis of the variable response to corticosteroid therapy seen in patients with AAH and to

235 tion of ipratropium bromide to albuterol and corticosteroid therapy significantly decreases the hospi

236 al insufficiency animal model, we found that corticosteroid therapy significantly improved the surviv

237 atment with elimination diets and/or topical corticosteroid therapy slow disease progression, but are

238 henotype, as treatment, including daily oral corticosteroid therapy, suppresses eosinophilic inflamma

239 domized controlled trial has been published, corticosteroid therapy, surgical decompression or observ

240 l II study and 6 level III studies) explored corticosteroid therapy that did not have uniformly bette

241 Patients were also randomly assigned to corticosteroid therapy that included either dexamethason

242 a within the first month after initiation of corticosteroid therapy that is attenuated during the sub

243 In all IAC patients, after 4 and 8 weeks of corticosteroid therapy the contribution of these IgG4+ c

244 eria (eg, lack of exacerbations and systemic corticosteroid therapy), the proposed definitions diverg

245 tent asthma controlled with low-dose inhaled corticosteroid therapy, the use of either biomarker-base

246 60 eyes in 40 patients who received topical corticosteroid therapy, there was a dose-dependent incre

247 ving tacrolimus/sirolimus and withdrawn from corticosteroid therapy three months after transplantatio

248 eases after more than 5 days of sCS systemic corticosteroid therapy; thus, imaging should not be dela

249 e contributions of systemic inflammation and corticosteroid therapy to bone loss.

250 However, the ability of corticosteroid therapy to improve mortality in patients

251 Systemic corticosteroid therapy to prevent BPD that was initiated

252 pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interfero

253 Treatment can be improved by continuing corticosteroid therapy until normal liver test results a

254 ortion in whom complete cessation of inhaled corticosteroid therapy was achieved (17.4 percent in the

255 Immediate intravenous corticosteroid therapy was administered, permitting to r

256 Systemic corticosteroid therapy was associated with improved visu

257 Corticosteroid therapy was associated with partial or no

258 Higher dose corticosteroid therapy was associated with significantly

259 Using a Cox proportional hazards model, corticosteroid therapy was associated with similar 30-da

260 AT and subsequently at the time that topical corticosteroid therapy was initiated.

261 risk of death or disability associated with corticosteroid therapy was inversely associated with the

262 Median duration of systemic corticosteroid therapy was lower in the eosinophil-guide

263 t reported the occurrence of adverse events, corticosteroid therapy was not associated with an increa

264 In logistic regression models, corticosteroid therapy was not associated with reduction

265 children with bacterial meningitis, adjuvant corticosteroid therapy was not associated with time to d

266 Systemic corticosteroid therapy was not significantly associated

267 Recently high-dose corticosteroid therapy was shown to reduce the duration

268 Intensified topical corticosteroid therapy was started immediately after dia

269 Corticosteroid therapy was started, and the patient was

270 Corticosteroid therapy was the treatment of choice in 38

271 Eyes treated with systemic corticosteroid therapy were identified for further analy

272 on showed that younger age, higher MELD, and corticosteroid therapy were independently associated wit

273 Adverse events associated with corticosteroid therapy were mild and transient.

274 omen (N = 46) receiving chronic prescription corticosteroid therapy were randomized to memantine or p

275 tis patients aged >or=50 years (or >or=40 on corticosteroid therapy) were randomly assigned to rofeco

276 to 4 acute GVHD, 91% responded to front-line corticosteroid therapy, whereas 50% responded in the SOC

277 -host disease (GVHD) from receiving systemic corticosteroid therapy, which impairs cellular immunity.

278 e anterior segment and manageable with local corticosteroid therapy, which justified the continuation

279 ce and predictors of AKI, the association of corticosteroid therapy with AKI risk, and factors associ

280 his study compares the analgesic efficacy of corticosteroid therapy with placebo.

281 zed, controlled trials, comparing adjunctive corticosteroid therapy with the standard of care alone f

282 to severe UC should undergo a course of oral corticosteroid therapy, with transition to 5-ASA, thiopu

283 ng-term sustained complete remission without corticosteroid therapy without any additional maintenanc

284 ifying children who are likely responders to corticosteroid therapy would be a major benefit in the m